ALPHARETTA, Ga., May 10, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter ended March 31, 2017 and provided an update on its development programs.
“The Clearside team continues our pursuit of transformative, elegant, precise solutions to restore and preserve vision,” said Daniel H. White, Chief Executive Officer and President. “Together, we continued to advance our pipeline in the first quarter of 2017 as our pivotal Phase 3 clinical trial for the treatment of macular edema associated with non-infectious uveitis continues enrollment with preliminary data expected in early 2018. We also enrolled the first patient in a Phase 3 clinical trial for the treatment of macular edema associated with retinal vein occlusion. Additionally, we received notices of allowance of two important U.S. patents, which are representative of a new family of patents that protect the unique drug distribution properties of injecting to the retinal and choroid through the suprachoroidal space.”